Kerry completed his PhD in Medical Statistics part-time, whilst working as a Statistician in the National Health Service in the UK. Following spells with Ciba-Geigy AG (now Novartis) in Basel, Switzerland and the University of Kent at Canterbury, UK, Kerry joined Quintiles in Bracknell, UK in 1993. He has gained considerable experience in the design, analysis and reporting of pre-clinical as well as Phase I, II, III and IV clinical trials, across a very wide range of therapeutic areas. He has been particularly involved with regulatory submissions in diabetes, migraine, Parkinson’s disease, transplantation and vaccines.

James joined AstraZeneca in November 2013 as the Head of Early Clinical Development Biometrics. After completing his MSc in Statistics at Imperial College, London, he began his career as a Research Fellow at the Applied Statistics Research Unit at the University of Kent, UK working for 5 years in various applications of statistics but particularly in the area of clinical cross-over trials, linear and non-linear modelling and Bayesian methods. He then completed 21 years at Amgen where he worked on the development and regulatory/ reimbursement approval of many of their biotechnology products, representing the company at regulatory submissions in the US and the EU and eventually chairing the company’s International Protocol Review Committee.